头颈癌质子治疗相关毒性、效用与患者报告结局的纵向研究
该前瞻性队列研究在荷兰质子治疗中心纳入2020年1月至2022年12月接受质子治疗(PT)的119例头颈癌(HNC)患者,采用EORTC-QLQ-C30、EQ-5D和EORTC-H&N-35问卷在治疗前及治疗后0、6、12、24个月评估健康相关生活质量(HRQoL)。结果显示治疗期间所有报告功能恶化,多数功能在6个月内恢复并超过基线;PT结束时效用较基线显著下降0.12分,6个月后恢复,治疗1年后进一步改善。研究还估算了口干、吞咽困难、黏膜炎和皮炎等放射性毒性的负效用值。
要点
- 119例HNC患者接受PT,治疗期间所有报告功能恶化,多数6个月内恢复并超过基线。
- PT结束时效用较基线显著下降0.12分,6个月后恢复,1年后进一步改善。
- 研究估算了口干、吞咽困难、黏膜炎和皮炎等毒性的负效用值,可用于PT经济评估。
核心结论
- 本研究呈现了毒性随时间对患者效用值的影响,并用患者报告的 symptom 和功能结果加以印证。
- 研究估算了口干、吞咽困难、黏膜炎和皮炎等每种放射性毒性的负效用值,可助力PT的经济学价值评估。
研究设计与样本
- 在荷兰一家质子治疗中心开展的前瞻性队列研究,采用EORTC-QLQ-C30、EQ-5D和EORTC-H&N-35问卷。
- 纳入2020年1月至2022年12月接受PT的119例头颈癌患者,问卷于治疗前及治疗后0、6、12、24个月发放。
- 采用广义估计方程分析效用变化及放射性毒性的负面影响。
主要发现
- 治疗期间所有报告功能均出现恶化,多数功能在6个月内恢复并改善至超过基线。
- PT结束时患者效用较基线显著下降0.12分,该效用损失在6个月后恢复,治疗1年后进一步改善。
- 研究提供了每种放射性毒性(包括口干、吞咽困难、黏膜炎和皮炎)的负效用估算。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In comparison to current standard photon irradiation, proton therapy (PT) significantly reduces dose to the surrounding normal tissue and therefore is expected to reduce toxicity and improve health related quality of life (HRQoL). Despite the high expectations of PT, there is very limited data on patients' HRQoL after radiotherapy. This study evaluated HRQoL in head and neck cancer (HNC) patients receiving PT and established a robust benchmark for future comparison of PT and the radiotherapy advancements. METHOD: A questionnaire-based (consisting of EORTC-QLQ-C30, EQ-5D, and EORTC-H&N-35) prospective cohort study was performed in a Dutch proton therapy center. HNC patients who received PT between January 2020 to December 2022 were enrolled in this study. The questionnaires were distributed pre-treatment, and 0, 6, 12, 24 months post-treatment. The generalized estimating equations method was used to analyze the utility change and negative impact of the radiation-related toxicities. RESULTS: 119 HNC patients were included in the study. Symptom and function scores showed the deterioration of all reported functions during the period of treatment. Most of the functions recovered within six months and improved beyond baseline. At the end of PT, the patients' utility decreased significantly (0.12 points) compared to the baseline. The loss in utility was recovered after six months and a further improvement was seen one year after the treatment. This study further provided the estimation of the disutility of each radiation related toxicity. CONCLUSION: The present study presented the impact of toxicity on patient's utility over time and further confirmed it with the results of patient-reported symptom and function. This study provided estimation of each radiation-related toxicity, including xerostomia, dysphagia, mucositis, and dermatitis, which could contribute to the value assessment through economic evaluations of PT.
引用
- Hsuan Chen Y, Kroesen M, Hoogeman M, et al. Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study. Clin Transl Radiat Oncol. 2025. PMID: 39898329. doi:10.1016/j.ctro.2025.100913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。